Velicept Therapeutics
Privately held clinical development
About Velicept Therapeutics
Velicept Therapeutics, Inc. was a clinical-stage pharmaceutical company focused on developing treatments for urological and gastrointestinal disorders. The company was formed in 2015 through a merger between NeXeption and AltheRx Pharmaceuticals to advance the development of its lead candidate, solabegron. The company was led by President and CEO, Dr. James Walker, an executive with prior experience at Schering-Plough and as the founder and CEO of Octagon Research Solutions, which was acquired by Accenture. Unfortunately, after raising significant capital and advancing its lead product through mid-stage clinical trials, the company appears to have ceased operations around July 2022.
Velicept's primary asset was solabegron, a highly selective beta-3 adrenoceptor agonist. This compound works by relaxing the bladder's smooth muscle, representing a different mechanism compared to many existing treatments. The company's business model was centered on the clinical development and eventual commercialization of solabegron. Its target market included patients suffering from overactive bladder (OAB) and irritable bowel syndrome (IBS), conditions affecting a large and growing segment of the population. Revenue would have been generated from the sale of the approved drug. The development of solabegron was originally initiated by GlaxoSmithKline before being acquired by AltheRx in 2011, and then subsequently by Velicept through the 2015 merger.
The company's strategy involved progressing solabegron through a series of clinical trials to establish its safety and efficacy. Completed Phase 2 studies for OAB showed that solabegron provided a statistically significant improvement in symptoms compared to a placebo, including a reduction in incontinence episodes and daily voids. An important feature noted in these studies was a tolerability profile similar to placebo, with patients not experiencing common side effects like dry mouth or changes in blood pressure. Velicept also developed a novel once-daily formulation to improve convenience and initiated Phase 2b studies to evaluate different dosages. In 2019, the company announced positive top-line results from one of its Phase 2b studies, which met its primary endpoint. Despite these promising clinical milestones and raising over $42 million in funding from investors like Samsara BioCapital, Longitude Capital, and Fountain Healthcare Partners, Velicept was ultimately put up for sale through an Assignment for the Benefit of Creditors in late 2020 and is now listed as out of business.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 50.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Nov 2019 | $6M | — | Undisclosed | — |
| SERIES B✓Equity / VC | Oct 2018 | $15M | $60M | Fountain Healthcare Partners · Longitude Capital · Samsara BioCapital | — |
Growth signals
Latest recorded traffic for Velicept Therapeutics is 480 monthly website visits, up 92% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Velicept Therapeutics in the Malvern ecosystem
The Velicept Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Longitude Capital
Samsara BioCapital
Fountain Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Velicept Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Velicept Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










